Publications by authors named "T Bogenrieder"

Claim this Profile
A
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Valentine M Macaulay, Simon Lord, Syed Hussain, José Pablo Maroto, Robert Hugh Jones, Thomas Bogenrieder

Br J Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHK1 inhibition exacerbates replication stress induced by IGF blockade.
Xiaoning Wu, Elena Seraia, Stephanie B Hatch, Xiao Wan, Daniel V Ebner, Thomas Bogenrieder

Oncogene· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors.
Keunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, Byoung Chul Cho, Sang-We Kim, Thomas Bogenrieder

JTO Clin Res Rep· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction.
Guillaume Rieunier, Xiaoning Wu, Letitia E Harris, Jack V Mills, Ashwin Nandakumar, Thomas Bogenrieder

Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Thomas Bogenrieder

Breast Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis